LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$24.00
-0.81 (-3.26%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 10, 2026
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LYEL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LYEL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $24.00, which is considered slightly low relative to its 30-day fair value range of $22.50 to $31.81.
Technical Outlook: Technically, LYEL is in a strong uptrend. Immediate support is located at $22.67, while resistance sits at $27.89. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: LYEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.67 (+19.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LYEL is in a strong uptrend. Immediate support is located at $22.67, while resistance sits at $27.89. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: LYEL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.67 (+19.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$22.50 -
$31.81
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading below Wall St target ($29.67)
Fair Price Analysis
30-Day Fair Range
$22.50 -
$31.81
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$4.13
(17.2%)
Support & Resistance Levels
Support Level
$22.67
Resistance Level
$27.89
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.74
Wall Street Target
$29.67
(+19.6%)
Revenue Growth (YoY)
-55.9%
Last updated: January 31, 2026 4:04 AM ET
Data refreshes hourly during market hours. Next update: 5:04 AM
Data refreshes hourly during market hours. Next update: 5:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles W Newton
SELL
136 shares
2025-08-12
Gary K Lee
SELL
136 shares
2025-08-12
Lynn Seely
SELL
406 shares
2025-08-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced LYEL Option Strategies
Professional options setups generated by AI based on today's LYEL price and gamma walls.
